Environmental protection in upcoming pharmaceutical legislation could be further improved to optimise risk

A new analysis of upcoming European pharmaceutical legislation reveals that while environmental risk assessments are set to become mandatory—with regulators gaining the power to reject drugs that fail—critical blind spots remain, potentially undermining the goal of cleaner waterways.

Legislative Progress and a Concrete Threshold

The draft EU pharmaceutical legislation, which achieved provisional agreement in late 2025, represents a significant policy shift. For the first time, it would formally link a drug's market authorization to passing an environmental risk assessment. This creates a tangible regulatory lever. The analysis, published by experts supported by the EU Horizon programme, confirms this as a positive step, noting the legislation’s intent to create a "future proof regulatory framework." The direct application of the regulation is anticipated within a few years of formal adoption, setting a clear deadline for the industry to adapt.

The Unresolved Problem of Chemical Cocktails

The experts pinpoint a major gap: the legislation does not fully account for the synergistic danger of chemical mixtures. Pharmaceuticals rarely exist in isolation in waterways. They mix with agricultural chemicals, consumer products, and other drugs, creating "cocktails" whose combined toxic effect can be greater than the sum of their parts. The review cites the example of two common antibiotics, sulfamethoxazole and trimethoprim, which together inflict serious damage on freshwater algae. While proposals exist within the EU’s broader chemical regulation (REACH) to estimate mixture risks, a parallel mechanism is not yet fully integrated into the pharmaceutical assessment framework. This omission could leave a significant pathway of environmental harm under-regulated.

Toward More Predictive and Efficient Assessment

Beyond mixtures, the analysis argues that current testing methodologies are too narrow. They focus on short-term, lethal effects on individual organisms, potentially missing subtler, population-level impacts like altered behavior or reduced fertility. The researchers advocate for a two-stage screening process: a broad, high-level initial assessment for all drugs, followed by a detailed investigation for those flagged as higher risk. They also suggest wider use of computer modelling to predict environmental effects based on a chemical's structure. This approach could optimize the assessment process, making it both more thorough where it matters and more efficient overall. As the legislation nears finalization, these data-driven refinements represent the next frontier for aligning drug innovation with planetary health.